Pulmonary Arterial Hypertension Market

DelveInsight’s ‘Pulmonary Arterial Hypertension Market Insights, Epidemiology and Market Forecast—2032’ report deliver an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

The Pulmonary Arterial Hypertension market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Pulmonary Arterial Hypertension symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Pulmonary Arterial Hypertension symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Geographies Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Pulmonary Arterial Hypertension Market: Understanding and Treatment Algorithm

Pulmonary Arterial Hypertension Overview

Pulmonary arterial hypertension (PAH) is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. PH is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization. The term PAH describes a subset of patients who also have the presence of pre-capillary hypertension, including an end-expiratory pulmonary artery wedge pressure (less than 15 mm Hg) and a pulmonary vascular resistance greater than 3 Woods units. PAH has three subgroups: idiopathic, heritable, and pulmonary arterial hypertension related to risk factors or associated conditions.

 

Elevated pulmonary vascular resistance is caused by the proliferation of endothelial and smooth muscle cells, causing tunica media hypertrophy of small-caliber pulmonary arteries. Moreover, the endothelial cells have impaired the production of nitric oxide and prostacyclin. Patients with idiopathic and heritable forms of pulmonary artery hypertension (HPAH) are distinguished by identifying an inheritable genetic mutation; whereas, idiopathic forms have an underlying genetic predisposition to develop pulmonary hypertension. Regardless, both forms have genetic mutations that overlap each disease process.

 

Pulmonary arterial hypertension (PAH) is most-commonly idiopathic and is characterized by increased vascular resistance and blood vessel narrowing within the pulmonary vasculature. Restricted flow through pulmonary arteries, as found in PAH, is thought to have molecular and genetic causes which lead to hypertrophy of smooth muscle, endothelial cells, and adventitia. In response to the increased resistance, the right ventricle will increase filling and stroke volume, increasing pulmonary arterial pressure. Over time, right ventricular hypertrophy develops. In the other groups of PH, increased pulmonary vascular resistance is similarly due to restricted flow, but it is typically secondary to another process such as left heart disease, chronic lung disease or chronic pulmonary thromboembolism.

 

The cardinal symptom of every form of pulmonary hypertension is progressive exercise dyspnea, often accompanied by fatigue and exhaustion. The symptoms are unspecific, so there is often a delay of many months or even years between the onset of symptoms and diagnosis. With the progression of the disease the symptoms become worse and new symptoms occur, e.g., dyspnea on bending down (bendopnea) and syncope, the latter particularly during or immediately after physical exertion. In patients with pulmonary hypertension, frequent syncope even on slight exertion clearly points to the presence of a life-threatening state associated with high mortality. In the event of cardiac decompensation the right cardiac filling pressures rise, with the typical triad of cervical venous congestion, ascites, and edema. The most frequently occurring signs, often subtle, are peripheral or central cyanosis (often only, or more strongly, during exercise), a pronounced pulmonary valve component of the second heart sound, and a systolic flow murmur reaching its maximum at a left parasternal location in tricuspid valve insufficiency.

 

Early detection and precise classification of the disease are the essential goals of diagnosis in pulmonary hypertension. With physical examination, the basic diagnostic tests in every case of uncertain or progressive exercise dyspnea should include ECG and determination of brain natriuretic peptide (BNP) or the N-terminal fragment of its precursor (NT-proBNP). If both of these show no abnormality, pulmonary hypertension is highly unlikely to be present. Further diagnostic investigations are required only in the case of strong clinical suspicion of pulmonary hypertension or if the results of the tests mentioned above are unclear. Pathologic ECG or BNP findings unequivocally indicate further cardio logical investigation.

 

Treatment of Pulmonary arterial hypertension (PAH) has progressed significantly over the past few decades in both its complexity and efficacy. The therapy aims to achieve a low-risk status (maintaining WHO-FC II if possible) to preserve patient function, quality of life and minimize mortality risk. This is generally achieved by optimizing the patient’s 6 minute walk distance (6MWD); however, current target thresholds rely upon cohort studies and expert consensus.

 

Pulmonary arterial hypertension (PAH) management involves a stepwise pragmatic approach from general supportive treatment up to targeted pharmacological interventions.  Selected patients undergo vasoreactivity testing, with those that exhibit sufficient vasodilation subsequently being commenced on regular high-dose calcium channel blockers (CCB). Patients  who  either  fail  to  qualify for  vasoreactivity  testing  or  demonstrate  inadequate  response  are  then  commenced  on  targeted monotherapy or combination therapies that counteract the pathophysiology of the condition.

 

The overall dynamics of the Pulmonary Arterial Hypertension (PAH) market is anticipated to change in the coming years owing to the expected launch of emerging therapies and others are developing treatments for pulmonary arterial hypertension (PAH).

 

Pulmonary Arterial Hypertension Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Pulmonary Arterial Hypertension market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, the Europe, and Japan.

 

The DelveInsight Pulmonary Arterial Hypertension market report gives a thorough understanding of Pulmonary Arterial Hypertension symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Pulmonary Arterial Hypertension algorithms and treatment guidelines in the US, the Europe, and Japan.

 

Pulmonary Arterial Hypertension Epidemiology

The epidemiology division’s Pulmonary Arterial Hypertension symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Pulmonary Arterial Hypertension epidemiology segmented as the Total Prevalence of Pulmonary Arterial Hypertension, Sub-type Specific Prevalence of Pulmonary Arterial Hypertension, and Gender specific Prevalence of Pulmonary Arterial Hypertension. The report includes the Pulmonary Arterial Hypertension scenario in the 7MM, covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

 Country Wise-Pulmonary Arterial Hypertension Epidemiology

The epidemiology segment also provides the Pulmonary Arterial Hypertension epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 7MM prevalent population of Pulmonary Arterial Hypertension were 69,605 cases in 2021.

 

Pulmonary Arterial Hypertension Drug Chapters

The drug chapter segment of the Pulmonary Arterial Hypertension report encloses the detailed analysis of Pulmonary Arterial Hypertension marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Pulmonary Arterial Hypertension clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Pulmonary Arterial Hypertension Emerging Drugs

 

Treprostinil Palmitil (Insmed Incorporated)

Treprostinil palmitil (TP) is a prodrug of treprostinil (TRE), a pulmonary vasodilator that has been previously formulated for inhaled administration via a nebulizer. TP demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo.

Products detail in the report…

Pulmonary Arterial Hypertension Market Outlook

The Pulmonary Arterial Hypertension market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Pulmonary Arterial Hypertension market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of Pulmonary Arterial Hypertension market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, Pulmonary Arterial Hypertension market in the 7MM is expected to change in the study period 2019-2032.

 

Key Findings

This section includes a glimpse of the Pulmonary Arterial Hypertension market in the 7MM. The market size of Pulmonary Arterial Hypertension in the seven major markets was found to be USD 4,775.54 million in 2021.

 

The United States Market Outlook

This section provides a total of Pulmonary Arterial Hypertension market size and market size by therapies in the United States.

 

The United States accounts for higher Pulmonary Arterial Hypertension market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

The EU-5 Countries: Market Outlook

The total Pulmonary Arterial Hypertension market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Pulmonary Arterial Hypertension market size and market size by therapies in Japan are also mentioned.

 

Pulmonary Arterial Hypertension Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019-2032. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

 

Pulmonary Arterial Hypertension Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Pulmonary Arterial Hypertension key players involved in developing targeted therapeutics.

 

Major players Sotatercept (Acceleron Pharma Inc.), Ralinepag (United Therapeutics), Rodatristat Ethyl (Altavant Sciences), and others are being assessed as potential therapies to be available in the market in the coming future.

 

Pulmonary Arterial Hypertension Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Pulmonary Arterial Hypertension emerging therapies.

 

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working on Pulmonary Arterial Hypertension domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Pulmonary Arterial Hypertension market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

 

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Pulmonary Arterial Hypertension Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Pulmonary Arterial Hypertension Market Report

  • The report covers the descriptive overview of Pulmonary Arterial Hypertension explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Pulmonary Arterial Hypertension epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Pulmonary Arterial Hypertension provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Pulmonary Arterial Hypertension market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Pulmonary Arterial Hypertension market

 

Pulmonary Arterial Hypertension Market Report Highlights

  • In the coming years, Pulmonary Arterial Hypertension market is set to change due to the rising awareness of the disease, resistant to the current antibiotic regime, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Arterial Hypertension R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Pulmonary Arterial Hypertension. The launch of emerging therapies will significantly impact the Pulmonary Arterial Hypertension market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Pulmonary Arterial Hypertension
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Pulmonary Arterial Hypertension Market Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pulmonary Arterial Hypertension Pipeline Analysis
  • Pulmonary Arterial Hypertension Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

 

Pulmonary Arterial Hypertension Market Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Pulmonary Arterial Hypertension Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Pulmonary Arterial Hypertension Market Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

 

Key Questions

Market Insights:

  • What was the Pulmonary Arterial Hypertension Market share (%) distribution in 2022, and how would it look in 2032?
  • What would be the Pulmonary Arterial Hypertension total market Size as well as market Size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the market key findings across 7MM, and which country will have the largest Pulmonary Arterial Hypertension market Size during the forecast period (2022–2032)?
  • At what CAGR, the Pulmonary Arterial Hypertension market is expected to grow by 7MM during the forecast period (2022–2032)?
  • What would be the Pulmonary Arterial Hypertension market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Pulmonary Arterial Hypertension market growth till 2032, and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Pulmonary Arterial Hypertension?
  • What is the historical Pulmonary Arterial Hypertension patient pool in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Pulmonary Arterial Hypertension in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Pulmonary Arterial Hypertension?
  • Out of all 7MM countries, which country would have the highest prevalent Pulmonary Arterial Hypertension population during the forecast period (2022–2032)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Pulmonary Arterial Hypertension?
  • What are the current treatment guidelines for treating Pulmonary Arterial Hypertension in the US, the Europe, and Japan?
  • What are the Pulmonary Arterial Hypertension marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Pulmonary Arterial Hypertension?
  • How many therapies are developed by each company for the treatment of Pulmonary Arterial Hypertension?
  • How many emerging therapies are in the mid-stage and late development stages to treat Pulmonary Arterial Hypertension?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Arterial Hypertension therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Pulmonary Arterial Hypertension and their status?
  • What are the key designations that have been granted for the emerging therapies for Pulmonary Arterial Hypertension?
  • What are the global historical and forecasted markets of Pulmonary Arterial Hypertension?

 

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Pulmonary Arterial Hypertension market
  • To understand the future market competition in the Pulmonary Arterial Hypertension market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension in the US, the Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension market
  • To understand the future market competition in the Pulmonary Arterial Hypertension market

Frequently Asked Questions

What is the Pulmonary Arterial Hypertension?
Pulmonary arterial hypertension is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. PH is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization.
Who are the leading companies in the Pulmonary Arterial Hypertension Market Landscape?
Some of the key players of Pulmonary Arterial Hypertension Market includes Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GSK, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, Bayer Group, Actelion Pharmaceuticals, Co Therix, Kaken Pharmaceutical, Sanofi-Aventis, Toray, Acceleron Pharma Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp & Dohme Corp., Insmed Incorporated, Pharmaosa Biopharma Inc., Bial (Portela C S.A.), Liquida Technologies, Inc., Cereno Scientific AB, and others.
What are the key strengths of Pulmonary Arterial Hypertension Market Report?
Key strengths of Pulmonary Arterial Hypertension Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers.
Which country is expected to account for the most significant prevalent cases for Pulmonary Arterial Hypertension in the 7MM?
The US is expected to account for the highest Pulmonary Arterial Hypertension prevalent cases.

1. Key Insights

2. Report Introduction

3. Pulmonary Arterial Hypertension Market Overview at a Glance

3.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2019

3.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2032

4. Executive Summary of Pulmonary Arterial Hypertension

5. Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification of Pulmonary Arterial Hypertension (PAH)

5.3.1. WHO classification

5.3.2. Functional Classification of Pulmonary Arterial Hypertension

5.4. Etiology

5.5. Risk factors

5.6. Pathophysiology

5.6.1. Nitric Oxide Pathway

5.6.2. Prostacyclin-Thromboxane A2 Pathway

5.6.3. Endothelin-1 Pathway

5.7. Diagnosis

6. Management and Treatment

6.1. Treatment Guidelines

6.1.1. CHEST Guidelines [The United States]

6.1.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines

7. Epidemiology and Patient Population

7.1. Key Findings

7.1.1. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension

7.2. Assumption and Rationale

7.3. The United States

7.3.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in the United States

7.3.2. Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in the United States

7.3.3. Gender specific Prevalence of Pulmonary Arterial Hypertension in the United States

7.4. The EU5

7.4.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in the EU5

7.4.2. Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in the EU5

7.4.3. Gender specific Prevalence of Pulmonary Arterial Hypertension in the EU5

7.5. Japan

7.5.1. Total Prevalent Patient Population of Pulmonary Arterial Hypertension in Japan

7.5.2. Sub-type Specific Prevalence of Pulmonary Arterial Hypertension in Japan

7.5.3. Gender specific Prevalence of Pulmonary Arterial Hypertensionin Japan

8. Patient Journey

9. Patient Journey

10. Marketed Therapies

10.1. Sildenafil (Revatio): Pfizer

10.1.1. Drug Description

10.1.2. Other Development Information

10.1.3. Safety and Efficacy

10.1.4. Product Profile

10.1.5. Analysts’ Views

10.2. Tadalafil (Adcirca): Eli Lilly and Company/United Therapeutics Corporation/Gilead Sciences/GSK/ICOS Corporation

10.2.1. Drug Description

10.2.2. Other Development Information

10.2.3. Safety and Efficacy

10.2.4. Product Profile

10.2.5. Analysts’ Views

10.3. Selexipag (Uptravi): Actelion Pharmaceuticals/Nippon Shinyaku

10.3.1. Drug Description

10.3.2. Other Development Information

10.3.3. Safety and Efficacy

10.3.4. Product Profile

10.3.5. Analysts’ Views

10.4. Treprostinil sodium (IV, SC): United Therapeutics Corporation

10.4.1. Drug Description

10.4.2. Other Development Information

10.4.3. Safety and Efficacy

10.4.4. Product Profile

10.4.5. Analysts’ Views

10.5. Tyvaso (Treprostinil Sodium, Inhaled): United Therapeutics Corporation

10.5.1. Drug Description

10.5.2. Other Development Information

10.5.3. Safety and Efficacy

10.5.4. Product Profile

10.5.5. Analysts’ Views

10.6. Adempas (Riociguat): Bayer Group

10.6.1. Drug Description

10.6.2. Other Development Information

10.6.3. Safety and Efficacy

10.6.4. Product Profile

10.6.5. Analysts’ Views

10.7. Ambrisentan: Gilead Sciences/GlaxoSmithKline

10.7.1. Drug Description

10.7.2. Other Development Information

10.7.3. Safety and Efficacy

10.7.4. Product Profile

10.7.5. Analysts’ Views

10.8. Macitentan: Actelion Pharmaceuticals

10.8.1. Drug Description

10.8.2. Other Development Information

10.8.3. Safety and Efficacy

10.8.4. Product Profile

10.8.5. Analysts’ Views

10.9. Tracleer: Actelion Pharmaceuticals

10.9.1. Drug Description

10.9.2. Other Development Information

10.9.3. Safety and Efficacy

10.9.4. Product Profile

10.10. Orenitram (Treprostinil diolamine, oral): United Therapeutics

10.10.1. Drug Description

10.10.2. Other Development Information

10.10.3. Safety and Efficacy

10.10.4. Product Profile

10.10.5. Analysts’ Views

10.11. Ventavis: Co Therix

10.11.1. Drug Description

10.11.2. Other Development Information

10.11.3. Safety and Efficacy

10.11.4. Product Profile

10.11.5. Analysts’ Views

10.12. Veletri (Epoprostenol): Actelion Pharmaceuticals

10.12.1. Drug Description

10.12.2. Other Development Information

10.12.3. Safety and Efficacy

10.12.4. Product Profile

10.13. Beraprost (TRK-100): Kaken Pharmaceutical/Sanofi-Aventis/Toray/United Therapeutics Corporation

10.13.1. Drug Description

10.13.2. Other Development Information

10.13.3. Safety and Efficacy

10.13.4. Product Profile

11. Emerging Therapies

11.1. Aurora-GT: United Therapeutics

11.1.1. Drug Descriptions

11.1.2. Other Developmental Activities

11.1.3. Clinical Development

11.1.4. Product Profile

11.1.5. Analysts’ Views

11.2. Sotatercept: Acceleron Pharma Inc.

11.2.1. Drug Descriptions

11.2.2. Other Developmental Activities

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Product Profile

11.2.6. Analysts’ Views

11.3. Ralinepag: United Therapeutics

11.3.1. Drug Description

11.3.2. Other Development Information

11.3.3. Clinical Development

11.3.4. Clinical Trials Information

11.3.5. Product Profile

11.3.6. Analysts’ Views

11.4. Rodatristat Ethyl: Altavant Sciences

11.4.1. Drug Description

11.4.2. Other Development Information

11.4.3. Clinical Development

11.4.4. Clinical Trials Information

11.4.5. Product Profile

11.4.6. Analysts’ Views

11.5. AV-101: Aerovate Therapeutics

11.5.1. Drug Description

11.5.2. Other Development Information

11.5.3. Clinical Development

11.5.4. Clinical Trials Information

11.5.5. Product Profile

11.5.6. Analysts’ Views

11.6. RT234: Respira Therapeutics

11.6.1. Drug Description

11.6.2. Other Development Information

11.6.3. Clinical Development

11.6.4. Clinical Trials Information

11.6.5. Product Profile

11.6.6. Analysts’ Views

11.7. GB002: Gossamer Bio Inc.

11.7.1. Drug Description

11.7.2. Other Development Information

11.7.3. Clinical Development

11.7.4. Clinical Trials Information

11.7.5. Product Profile

11.7.6. Analysts’ Views

11.8. MK5475: Merck Sharp & Dohme Corp.

11.8.1. Drug Description

11.8.2. Clinical Development

11.8.3. Clinical Trials Information

11.8.4. Product Profile

11.8.5. Analysts’ Views

11.9. Treprostinil Palmitil: Insmed Incorporated

11.9.1. Drug Description

11.9.2. Clinical Development

11.9.3. Clinical Trials Information

11.9.4. Product Profile

11.9.5. Analysts’ Views

11.10. L606: Pharmaosa Biopharma Inc.

11.10.1. Drug Description

11.10.2. Clinical Development

11.10.3. Clinical Trials Information

11.10.4. Product Profile

11.10.5. Analysts’ Views

11.11. Zamicastat (BIA-5-1058): Bial (Portela C S.A.)

11.11.1. Drug Descriptions

11.11.2. Other Developmental Activities

11.11.3. Clinical Development

11.11.4. Clinical Trials Information

11.11.5. Product Profile

11.11.6. Analysts’ Views

11.12. LIQ-861: Liquida Technologies, Inc.

11.12.1. Drug Description

11.12.2. Other Development Information

11.12.3. Clinical Development

11.12.4. Clinical Trials Information

11.12.5. Product Profile

11.12.6. Analysts’ Views

11.13. CS1: Cereno Scientific AB

11.13.1. Drug Descriptions

11.13.2. Other Developmental Activities

11.13.3. Clinical Development

11.13.4. Clinical Trials Information

11.13.5. Product Profile

11.13.6. Analysts’ Views

12. Other Therapies: Generics

12.1. Calcium Channel Blockers

12.2. Blood Thinners

12.3. Diuretics

12.4. Digoxin (Lanoxin)

13. Pulmonary Arterial Hypertension: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Size of Pulmonary Arterial Hypertension in 7MM

13.3. Market Size of Pulmonary Arterial Hypertension by Therapies in the 7MM

14. Market Outlook

14.1. United States Market Size

14.1.1. Total Market Size of Pulmonary Arterial Hypertension in the United States

14.1.2. Market Size of Pulmonary Arterial Hypertension by Therapies in the United States

14.2. EU-5 Market Size

14.2.1. Total Market size of Pulmonary Arterial Hypertension in the EU5

14.2.2. Market Size of Pulmonary Arterial Hypertensionby Therapies in the EU5

14.3. Japan

14.3.1. Total Market size of Pulmonary Arterial Hypertension in Japan

14.3.2. Market Size of Pulmonary Arterial Hypertension by Therapies in Japan

15. KOL Views

16. Unmet Needs

17. SWOT Analysis

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Pulmonary Arterial Hypertension, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Clinical features

Table 3: Clinical features

Table 4: Total Prevalent Patient Population of Pulmonary Arterial Hypertension in 7MM (2019–2032)

Table 5: Total Prevalent Patient Population and Diagnosed Cases of Pulmonary Arterial Hypertension in the United States (2019–2032)

Table 6: Sub-type Specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in the United States (2019–2032)

Table 7: Gender specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in United States (2019–2032)

Table 8: Total Prevalent Patient Population and Diagnosed Cases of Pulmonary Arterial Hypertension in the EU5 (2019–2032)

Table 9: Sub-type Specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in the EU5 (2019-2032)

Table 10: Gender specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in the EU5 (2019–2032)

Table 11: Total Prevalent Patient Population and Diagnosed Cases of Pulmonary Arterial Hypertension in Japan (2019–2032)

Table 12: Sub-type Specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in Japan (2019–2032)

Table 13: Gender specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in Japan (2019–2032)

Table 14: Sotatercept, Clinical Trial Description, 2022

Table 15: Ralinepag, Clinical Trial Description, 2022

Table 16: Rodatristat Ethyl, Clinical Trial Description, 2021

Table 17: AV-101, Clinical Trial Description, 2021

Table 18: RT234, Clinical Trial Description, 2022

Table 19: GB002, Clinical Trial Description, 2022

Table 20: MK-5475, Clinical Trial Description, 2022

Table 21: Treprostinil Palmitil, Clinical Trial Description, 2022

Table 22: L606, Clinical Trial Description, 2022

Table 23: Zamicastat Clinical Trial Description, 2022

Table 24: LIQ-861, Clinical Trial Description, 2022

Table 25: CS1, Clinical Trial Description, 2022

Table 26: 7 Major Market Size of Pulmonary Arterial Hypertension in USD Million (2019–2032)

Table 27: United States Market Size of Pulmonary Arterial Hypertension in USD Million (2019–2032)

Table 28: United States Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2019–2032)

Table 29: EU5 Market Size of Pulmonary Arterial Hypertension in USD Million (2019–2032)

Table 30: EU5 Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2019–2032)

Table 31: Japan Market Size of Pulmonary Arterial Hypertension in USD Million (2019–2032)

Table 32: Japan Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2019–2032)

List of Figures

Figure 1: Some of the common signs & symptoms of Pulmonary Arterial Hypertension (PAH)

Figure 2: Depiction of a Persistent Epithelial Defect (PED)

Figure 3: Functional Classification of PAH

Figure 4: Risk Factors of Pulmonary Arterial Hypertension

Figure 5: Pathophysiology of Pulmonary Arterial Hypertension (PAH)

Figure 6: Pathophysiology of Pulmonary Arterial Hypertension (PAH)

Figure 7: Diagnosis Algorithm of Pulmonary Arterial Hypertension (PAH)

Figure 8: Treatment Options for Pulmonary Arterial Hypertension (PAH)

Figure 9: Treatment Algorithm of Pulmonary Arterial Hypertension (PAH)

Figure 10: Total Prevalent Population of Pulmonary Arterial Hypertension in 7MM (2019-2032)

Figure 11: Total Prevalent Patient Population and Diagnosed Cases of Pulmonary Arterial Hypertension in the United States (2019–2032)

Figure 12: Sub-type Specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in the United States (2019–2032)

Figure 13: Gender specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in United States (2019–2032)

Figure 14: Total Prevalent Patient Population and Diagnosed Cases of Pulmonary Arterial Hypertension in the EU5 (2019–2032)

Figure 15: Sub-type Specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in the EU5 (2019-2032)

Figure 16: Gender specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in the (2019–2032)

Figure 17: Total Prevalent Patient Population and Diagnosed Cases of Pulmonary Arterial Hypertension in Japan (2019–2032)

Figure 18: Sub-type Specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in Japan (2019–2032)

Figure 19: Gender specific Diagnosed Prevalent cases of Pulmonary Arterial Hypertension in Japan (2019–2032)

Figure 20: 7 Major Market Size of Pulmonary Arterial Hypertension in USD Million (2019–2032)

Figure 21: 7 Major Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2019–2032)

Figure 22: Total Market Size of Pulmonary Arterial Hypertensionin the United States, USD Million (2019–2032)

Figure 23: The United States Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2019–2032)

Figure 24: Total Market Size of Pulmonary Arterial Hypertension in the EU5, USD Million (2019–2032)

Figure 25: The EU5 Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2019–2032)

Figure 26: Market Size of Pulmonary Arterial Hypertension in the Japan, USD Million (2019–2032)

Figure 27: The Japan Market Size of Pulmonary Arterial Hypertension by Therapies in USD Million (2019–2032)

Pfizer
Eli Lilly and Company
United Therapeutics Corporation
Gilead Sciences
GSK
ICOS Corporation
Actelion Pharmaceuticals
Nippon Shinyaku
Bayer Group
Actelion Pharmaceuticals
Co Therix
Kaken Pharmaceutical
Sanofi-Aventis
Toray
Acceleron Pharma Inc.
Altavant Sciences
Aerovate Therapeutics
Respira Therapeutics
Gossamer Bio Inc.
Merck Sharp & Dohme Corp.
Insmed Incorporated
Pharmaosa Biopharma Inc.
Bial (Portela C S.A.)
Liquida Technologies, Inc.
Cereno Scientific AB

 

Forward to Friend

Need A Quote